{"classes":[{"categories":[{"measurements":[{"groupId":"OG003","spread":"0.002300","value":"0.007163"},{"groupId":"OG004","spread":"0.002940","value":"0.005417"},{"groupId":"OG005","spread":"0.001460","value":"0.003352"},{"groupId":"OG006","spread":"0.0007292","value":"0.003522"},{"groupId":"OG007","spread":"0.001239","value":"0.002923"},{"groupId":"OG008","spread":"0.0006234","value":"0.002840"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"8"},{"groupId":"OG007","value":"4"},{"groupId":"OG008","value":"4"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Flat dose level; 0.15mg (Dose Level 1)","id":"OG000","title":"Part A Dose Level 1 NM21-1480-Q2W 0.15mg"},{"description":"Flat dose level; 1.5mg (Dose Level 2)","id":"OG001","title":"Part A Dose Level 2 NM21-1480-Q2W 1.5mg"},{"description":"Flat dose level; 8mg (Dose Level 3)","id":"OG002","title":"Part A Dose Level 3 NM21-1480-Q2W 8mg"},{"description":"Flat dose level; 24mg (Dose Level 4)","id":"OG003","title":"Part A Dose Level 4 NM21-1480-Q2W 24mg"},{"description":"Flat dose level; 80mg (Dose Level 5)","id":"OG004","title":"Part A Dose Level 5 NM21-1480-Q2W 80mg"},{"description":"Flat dose level; 240mg (Dose Level 6)","id":"OG005","title":"Part A Dose Level 6 NM21-1480-Q2W 240mg"},{"description":"Flat dose level; mg800 (Dose Level 7)","id":"OG006","title":"Part A Dose Level 7 NM21-1480-Q2W 800mg"},{"description":"This part of the study consisted of a 1400mg flat dose across one cohort.","id":"OG007","title":"Part A2 NM21-1480-Q2W"},{"description":"This part of the study consisted of a 800mg flat dose across three cohorts.","id":"OG008","title":"Part B NM21-1480-Q2W"}],"paramType":"MEAN","populationDescription":"Lambda z determined at C1 for all dose levels with the exception of Part A Dose Level 1,2 and 3. Lower limit of quantification (LLOQ) of NM21-1480 = 5 ng/mL. The constant Lambda z and its derived parameters meet one of the following conditions: the adjusted regression coefficient is less than 0.8 or the AUC%extrap exceeds 20%.","reportingStatus":"POSTED","timeFrame":"From baseline to up to 12 weeks post last dose, up to 48 weeks.","title":"Assessment of the Terminal Phase (Apparent Elimination) Rate Constant (λz)","type":"SECONDARY","unitOfMeasure":"1/h"}